Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15430938 | 0.80 | ACHE (0.43) | ACHEFAAHABCC4CACNA1FPDE5A | |
| SCHEMBL4878163 | 0.78 | ACHE (0.68) | ACHEKDM4EFAAHABCC4CACNA1F | |
| SCHEMBL4877278 | 0.78 | ACHE (0.54) | ACHEFAAHABCC4CACNA1FPDE5A | |
| SCHEMBL1114944 | 0.76 | ACHE (0.63) | ACHEKDM4EFAAHABCC4CACNA1F | |
| SCHEMBL29550221 | 0.76 | ACHE (0.63) | ACHEKDM4EFAAHABCC4CACNA1F | |
| Hydrochloric Acid SCHEMBL4833887 | 0.75 | ACHE (0.61) | ACHEKDM4EFAAHABCC4CACNA1F | |
| SCHEMBL28409784 | 0.75 | ACHE (0.61) | ACHEKDM4EFAAHABCC4CACNA1F | |
| SCHEMBL4843083 | 0.74 | METAP1 (0.58) | ACHEFAAHABCC4CACNA1FPDE5A | |
| SCHEMBL14156625 | 0.73 | ACHE (0.54) | ACHEKDM4EFAAHABCC4CACNA1F | |
| SCHEMBL4834272 | 0.72 | METAP1 (0.60) | ACHEFAAHABCC4CACNA1FPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446203-B2 | Preparation of intermediates for acetycholinesterase inhibitors | HETERO DRUGS LIMITED (IN) | 2008-11-04 | — | — | US | disclosed |
| EP-1654230-A1 | PREPARATION OF INTERMEDIATES FOR ACETYL CHOLINESTERASE INHIBITORS | Hetero Drugs Limited (IN) | 2006-05-10 | — | — | EP | disclosed |
| US-20060041140-A1 | 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone is hydrogenated using platinum oxide catalyst in the presence of hydrochloric acid under a pressure of 2 bars to give 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride | HETERO DRUGS LIMITED (IN) | 2006-02-23 | — | — | US | disclosed |
| WO-2005003092-A1 | PREPARATION OF INTERMEDIATES FOR ACETYL CHOLINESTERASE INHIBITORS | HETERO DRUGS LIMITED (IN) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041140-A1 | 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone is hydrogenated using platinum oxide catalyst in the presence of hydrochloric acid under a pressure of 2 bars to give 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride | ACHE, IDH2, IMPDH2 | ACHE 1/4885KDM4E 51/4885LMNA 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.